admin | May 3, 2021
The Belgian Journal of Hematology recently published their review of the state of JAK Inhibitors. Since its discovery in 2005 several companies have been working on creating a JAK Inhibitor for treatment of the myeloproliferative neoplasms.
Click here to read the full article (PDF)
Current trials for polycythemia vera, essential thrombocythemia and myelofibrosis (including those actively recruiting participants) can be found on our own clinical trials page.